S&P 5007,666.60▲0.5% Nasdaq26,217.83▲0.5% Dow53,061.95▲0.6% Russell 2K2,953.17▲1.1% 10-Yr4.80%+0bp VIX15.20−1.14 WTI$90.70▲0.5% Gold$4,431.70▲1.9% EUR/USD1.159▼0.1% BTC$78,715▼0.5% Nikkei66,215▼0.1%
At close · Thu, Sep 3, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Cholesterol drug setback raises pressure in lower Lp(a…

Cholesterol drug setback raises pressure in lower Lp(a) race

Novartis failure intensifies scrutiny on Amgen and Eli Lilly as they try to translate lower Lp(a) levels into fewer heart attacks and strokes.

Reported · Written up by our desk · Previews

CNBC Markets reports that Novartis’ failure in a lower Lp(a) cholesterol drug effort has increased uncertainty for other companies pursuing the same cardiovascular strategy.

The setback raises the stakes for Amgen and Eli Lilly, which are working to turn reductions in Lp(a) into measurable declines in heart attacks and strokes.

The reports frame the development as a risk to the broader multibillion-dollar race aimed at proving that lowering Lp(a) can improve clinical outcomes.

← Newer storyOpenAI chief scientist urges voluntary slowdowns in AI development

More like this

EarningsDell shares soar as AI orders lift earnings growth outlook
EarningsGoodyear extends Goodyear Forward turnaround plan as targets lag
EarningsVaxcyte readies Phase 3 results for VAX-31 after Q2 update
EarningsCostco posts August sales growth as digital orders accelerate
EarningsATI expects to deliver most of its record backlog in the next year

Sources

CNBC MarketsCholesterol drug setback casts doubt over multibillion-dollar race

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.